Spots Global Cancer Trial Database for Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Official Title: Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study
Study ID: NCT03797625
Conditions
Study Description
Brief Summary: The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens
Detailed Description: This study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens used as second-line treatment of advanced esophageal squamous cell carcinomas
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer hospital Fudan University, Shanghai, Shanghai, China
Contact Details
Name: chang jian hua, PD
Affiliation: PI
Role: PRINCIPAL_INVESTIGATOR
Name: wang hui jie, doctor
Affiliation: SUBI
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
